What is it about?
rLd-iPGAM is a drug target. This protein also induces immunoactivation in mononuclear cells (MNCs) of healthy, treated visceral leishmaniasis subjects and THP-1 cell lines. Since it has been tested on clinical samples; its applicability is very high in comparison to those tested on murine models. This protein not only amplify immune response but also translate it into microbicidal efficacy of phagocytic cells. In silico analysis also suggests the presence of MHC I and II restricted epitopes in iPGAM, which can trigger both CD8+ and CD4+ cells. Based on immunoprophylactic efficacy, rLdiPGAM can be used in future vaccine designs.
Featured Image
Why is it important?
There is no vaccine for Ileishmaniasis. It will help in the formulation of a vaccine for leishmaniasis.
Perspectives
What can be a vaccine candidate for any disease? A vaccine candidate must have the potency to uplift immune response in healthy individuals (otherwise it can not be a vaccine candidate) and in treated/cured patients (to assure specific immunity as a generalised high immunity is not good). This study has taken care of this issue and this is the advantage of this study.
Shubhankar Kumar Singh
ICMR-Rajendra Memorial Research Institute of Medical Sciences, Patna, India.
Read the Original
This page is a summary of: Co-factor-independent phosphoglycerate mutase of Leishmania donovani modulates macrophage signalling and promotes T-cell repertoires bearing epitopes for both MHC-I and MHC-II, Parasitology, November 2017, Cambridge University Press,
DOI: 10.1017/s0031182017001494.
You can read the full text:
Contributors
The following have contributed to this page
